秋水仙碱在急性心肌梗死中的应用
该多中心2×2析因试验将心肌梗死患者随机分配至秋水仙碱组或安慰剂组(同时随机分配至螺内酯组或安慰剂组),本文报告秋水仙碱部分结果。共纳入14个国家104个中心7062例患者,主要疗效终点为心血管死亡、再发心肌梗死、卒中或非计划缺血驱动冠状动脉血运重建的复合终点。中位随访3年,秋水仙碱组主要终点事件322/3528例(9.1%),安慰剂组327/3534例(9.3%)(HR 0.99;95%CI 0.85–1.16;P=0.93)。3个月时校正基线后C反应蛋白最小二乘均值差为-1.28 mg/L(95%CI -1.81至-0.75);腹泻发生率秋水仙碱组10.2% vs 安慰剂组6.6%(P<0.001),严重感染发生率两组无差异。
要点
- 心肌梗死后早期启动秋水仙碱并中位持续3年,主要复合终点发生率秋水仙碱组9.1% vs 安慰剂组9.3%(HR 0.99;95%CI 0.85–1.16;P=0.93),未降低。
- 主要终点各单项组分发生率两组看起来相似。
- 3个月时C反应蛋白校正基线后组间最小二乘均值差为-1.28 mg/L(95%CI -1.81至-0.75),秋水仙碱组较低。
- 腹泻发生率秋水仙碱组10.2% vs 安慰剂组6.6%(P<0.001),严重感染发生率两组无差异。
- 共7062例患者、104个中心、14个国家随机;分析时45例(0.6%)生命状态未知,最可能为随机缺失。
适用人群与场景
- 发生心肌梗死的患者,随机分组在心肌梗死后不久启动研究治疗。
- 多中心试验,纳入14个国家104个中心共7062例患者。
处置流程与药物剂量
- 患者随机接受秋水仙碱或安慰剂,同时按2×2析因设计随机接受螺内酯或安慰剂;本文报告秋水仙碱与安慰剂比较结果。
- 秋水仙碱在心肌梗死后不久启动,中位持续3年。
- 3个月时在部分患者亚组中测定C反应蛋白。
研究设计与关键结果
- 多中心2×2析因随机试验,7062例心肌梗死患者,104个中心,14个国家;秋水仙碱组3528例,安慰剂组3534例。
- 主要疗效终点为心血管死亡、再发心肌梗死、卒中或非计划缺血驱动冠状动脉血运重建的复合终点,采用时间-事件分析。
- 中位随访3年,主要终点事件秋水仙碱组322/3528例(9.1%)vs 安慰剂组327/3534例(9.3%)(HR 0.99;95%CI 0.85–1.16;P=0.93)。
- 主要终点各单项组分发生率两组看起来相似。
- 3个月时C反应蛋白校正基线后组间最小二乘均值差为-1.28 mg/L(95%CI -1.81至-0.75)。
- 腹泻发生率秋水仙碱组10.2% vs 安慰剂组6.6%(P<0.001);严重感染发生率两组无差异。
- 分析时45例(0.6%)生命状态未知,最可能为随机缺失。
证据类型、等级与局限
- 证据类型:多中心随机对照试验(2×2析因设计)。
- 加拿大卫生研究院等资助;CLEAR试验,ClinicalTrials.gov注册号NCT03048825。
- 局限:分析时45例(0.6%)生命状态未知,最可能为随机缺失。
对床旁实践的改变
- 心肌梗死后早期启动秋水仙碱并中位持续3年未降低主要复合终点,不支持以降低该复合终点为目的常规使用。
- 秋水仙碱组腹泻发生率高于安慰剂组(10.2% vs 6.6%;P<0.001),严重感染发生率两组无差异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Inflammation is associated with adverse cardiovascular events. Data from recent trials suggest that colchicine reduces the risk of cardiovascular events.
METHODS: In this multicenter trial with a 2-by-2 factorial design, we randomly assigned patients who had myocardial infarction to receive either colchicine or placebo and either spironolactone or placebo. The results of the colchicine trial are reported here. The primary efficacy outcome was a composite of death from cardiovascular causes, recurrent myocardial infarction, stroke, or unplanned ischemia-driven coronary revascularization, evaluated in a time-to-event analysis. C-reactive protein was measured at 3 months in a subgroup of patients, and safety was also assessed.
RESULTS: A total of 7062 patients at 104 centers in 14 countries underwent randomization; at the time of analysis, the vital status was unknown for 45 patients (0.6%), and this information was most likely missing at random. A primary-outcome event occurred in 322 of 3528 patients (9.1%) in the colchicine group and 327 of 3534 patients (9.3%) in the placebo group over a median follow-up period of 3 years (hazard ratio, 0.99; 95% confidence interval [CI], 0.85 to 1.16; P = 0.93). The incidence of individual components of the primary outcome appeared to be similar in the two groups. The least-squares mean difference in C-reactive protein levels between the colchicine group and the placebo group at 3 months, adjusted according to the baseline values, was -1.28 mg per liter (95% CI, -1.81 to -0.75). Diarrhea occurred in a higher percentage of patients with colchicine than with placebo (10.2% vs. 6.6%; P<0.001), but the incidence of serious infections did not differ between groups.
CONCLUSIONS: Among patients who had myocardial infarction, treatment with colchicine, when started soon after myocardial infarction and continued for a median of 3 years, did not reduce the incidence of the composite primary outcome (death from cardiovascular causes, recurrent myocardial infarction, stroke, or unplanned ischemia-driven coronary revascularization). (Funded by the Canadian Institutes of Health Research and others; CLEAR ClinicalTrials.gov number, NCT03048825.).
参考来源
- Jolly SS, d'Entremont MA, Lee SF, et al. Colchicine in Acute Myocardial Infarction. N Engl J Med. 2024. PMID: 39555823. doi:10.1056/NEJMoa2405922
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。